Evidence map›Paper›PMID 37062055›Full record

ArticleJournal of endocrinological investigation2023

GHRH + arginine test and body mass index: do we need to review diagnostic criteria for GH deficiency?

V Gasco, D Cuboni, E Varaldo, F Bioletto, A M Berton, C Bona, N Prencipe, E Ghigo, M Maccario, S Grottoli

Open access · hybridAbstract read
In one paragraph

Article in Journal of endocrinological investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

V GascoDepartment of Medical Science, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.ORCID http://orcid.org/0000-0002-6491-5731
D CuboniDepartment of Medical Science, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
E VaraldoDepartment of Medical Science, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
F BiolettoDepartment of Medical Science, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
A M BertonDepartment of Medical Science, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
C BonaDepartment of Medical Science, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
N PrencipeDepartment of Medical Science, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
E GhigoDepartment of Medical Science, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
M MaccarioDepartment of Medical Science, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
S GrottoliDepartment of Medical Science, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy. silvia.grottoli@unito.it.
University of Turin · ITDepartment of Medical Sciences · BY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe proportion of patients with low GH response to provocative tests increases with the number of other pituitary hormone deficiencies, reason why in panhypopituitary patients GH stimulation tests may be unnecessary to diagnose GH deficiency (GHD) PURPOSE: To re-evaluate the diagnostic cut-offs of GH response to GHRH + arginine (ARG) test related to BMI, considering the patients' pituitary function as the gold standard for the diagnosis of GHD.

methodsThe GH responses to GHRH + ARG were studied in 358 patients with history of hypothalamic-pituitary disease. GHD was defined by the presence of at least 3 other pituitary deficits (n = 223), while a preserved somatotropic function was defined by the lack of other pituitary deficits and an IGF-I SDS ≥ 0 (n = 135). The cut-off with the best sensitivity (SE) and specificity (SP), was identified for each BMI category using the ROC curve analysis. To avoid over-diagnosis of GHD we subsequently searched for the cut-offs with a SP ≥ 95%.

resultsThe best GH cut-off was 8.0 μg/l (SE 95%, SP 100%) in lean, 7.0 μg/l (SE 97.3%, SP 82.8%) in overweight, and 2.8 μg/l (SE 84.3%, SP 91.7%) in obese subjects. The cut-off with a SP ≥ 95% was 2.6 μg/l (SE 68.5%, SP 96.6%) in overweight and 1.75 μg/l (SE 70.0%, SP 97.2%) in obese subjects.

conclusionsThis is the first study that evaluates the diagnostic cut-offs of GH response to GHRH + ARG related to BMI using a clinical definition of GHD as gold standard. Our results suggest that with this new approach, the GHRH + ARG cut-offs should be revised to avoid GHD over-diagnosis.

Indexed as

Dwarfism, PituitaryHuman Growth HormonePituitary DiseasesArginineBody Mass IndexGrowth Hormone-Releasing HormoneHumansOverweightArginineGrowth Hormone-Releasing HormoneHuman Growth HormoneDiagnosisGH deficiencyGHRH + arginineObesitySensibilitySpecificity

Identifiers

PMID37062055
PMCPMC10514141
OpenAlexW4365997923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.